Marriage?? Young Americans Aren't Even Shacking Up
You’ve probably heard that marriage among young adults has been on the decline, but a new Gallup poll finds that the percentage of 18-to-29-year-olds living with a partner has flatlined in recent years.
“This means that not only are fewer young adults married, but also that fewer are in committed relationships,” Gallup’s Lydia Saad wrote Monday. “As a result, the percentage of young adults who report being single and not living with someone has risen dramatically in the past decade.”
Related: The Bad News About All the Singles in America
That percentage has risen from 52 percent in 2004 to 64 percent last year, Gallup says. The data doesn’t necessarily mean young adults are avoiding relationships entirely. Young people are just less likely to make a serious commitment associated with moving in together.
The trend hasn’t carried through to Americans in their 30s, who are only a bit more likely to be single than they were a decade ago. Marriage among people in this age group has also declined in popularity, but the percentage of 30-somethings living with a partner has jumped from 7 percent to 13 percent.
The new data suggests that, if young people don’t feel ready for marriage, they may not feel up for long-term commitment yet, either. (In some cases, that may be because they’re still living with their parents.) “This doesn't necessarily mean young adults are staying out of relationships, just that they are less likely to be making the more serious commitment associated with moving in together — whether in marriage or not,” Saad wrote.
The societal question, she said, is whether those single 20-somethings stay that way into their 30s. A Gallup poll from 2013 suggests that young adults may not be avoiding marriage altogether, but are just pushing it back. In that survey, 56 percent of Americans aged 18 to 34 said they were unmarried but did want to tie the knot at some point. Only 9 percent in the same age group said they were unmarried and wanted to stay that way. The most common reasons people listed for not being married yet included having not found the right person, being too young or not ready to get married and money concerns.
In other words, they might someday say “I do,” but for now they definitely don’t.
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.